Subscribe
shutterstock_779236312_laborant
laborant / Shutterstock.com
13 February 2019Americas

Boehringer Ingelheim teams up with IBM to explore blockchain

The Canadian units of IBM and pharmaceutical company  Boehringer Ingelheim have united to explore the use of blockchain technology in clinical trials.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FDA selects Merck, IBM, KPMG and Walmart for blockchain pilot
17 June 2019   The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
Americas
IBM patent targets blockchain in open scientific research
14 November 2018   Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
FDA selects Merck, IBM, KPMG and Walmart for blockchain pilot
17 June 2019   The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
Americas
IBM patent targets blockchain in open scientific research
14 November 2018   Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.

More on this story

Americas
FDA selects Merck, IBM, KPMG and Walmart for blockchain pilot
17 June 2019   The US Food and Drug Administration has chosen Merck & Co, IBM, KPMG, and Walmart to form a pilot project aimed at evaluating the use of blockchain to protect pharmaceutical product integrity.
Big Pharma
Boehringer teams up with Gubra to develop second obesity treatment
30 May 2019   German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
Americas
IBM patent targets blockchain in open scientific research
14 November 2018   Technology company IBM is seeking to patent the use of blockchain in open scientific research, including experiments, data collection, and analysis.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?